
Nyxoah SA (NYXH) Stock Forecast & Price Target
Nyxoah SA (NYXH) Analyst Ratings
Bulls say
Nyxoah is a medical technology company with a promising outlook, as evidenced by its strong Q1 net-revenue of €6.4M and its increasing sales force, which is expected to continue growing. The company is on track to submit a PMA supplement for a complete concentric collapse indication in Q3 or early Q4, with U.S. label expansion expected by 2027. Despite a lower valuation multiple due to sector trends, Nyxoah's FY26 revenue guidance of €36-40M is above the Street's estimate and shows potential for the company to become a high-growth asset. Additional positive developments, such as the completion of the ACCCESS study in late June or early July 2026, could further boost investor confidence in the company's potential.
Bears say
Nyxoah is showing strong revenue growth and maintaining its guidance, however, its gross margin and operating expenses are not meeting expectations. Additionally, there may be confusion and risks regarding the adoption of its technology and potential for further funding needs. While the recent U.S. launch has been successful, potential bottlenecks in the reimbursement process and volatility in the market may impact the company's future performance.
This aggregate rating is based on analysts' research of Nyxoah SA and is not a guaranteed prediction by Public.com or investment advice.
Nyxoah SA (NYXH) Analyst Forecast & Price Prediction
Start investing in Nyxoah SA (NYXH)
Order type
Buy in
Order amount
Est. shares
0 shares